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Introduction
Neuromyelitis optica spectrum disorders (NMOSDs) are 
inflammatory disorders of the central nervous system char-
acterized by simultaneous or recurrent immune mediated 
demyelination and axonal damage to the optic nerves and the 
spinal cord. The average age of onset is 41 years with a female 
to male ratio of 6.5:1.1 The patients typically present with 
acute attacks of optic neuritis and/or transverse myelitis. 
Initially, they were thought to be subtypes of multiple sclero-
sis (MS); however, they are now recognized as separate enti-
ties based on pathogenesis, imaging, biomarkers, and 
response to treatment.
Case Description
A 59-year-old woman with past medical history significant 
for hypertension, hyperlipidemia, and vertigo was admitted 
for left upper and lower extremity weakness and left shoul-
der pain for 2 days. She denied trauma, recent infection, par-
esthesia, cramps, facial droop, aphasia, urinary, or bowel 
incontinence, and there were no constitutional symptoms. 
Her history was negative for malignancy and autoimmune 
disorders.
On examination, the patient had a heart rate of 83, res-
piratory rate of 16, blood pressure of 139/96, and an oxygen 
saturation of 96% on room air. Neurological examination 
showed normal mentation but unsteady gait. Cranial nerves 
2 to 12 were grossly intact. Motor strength was 5/5 in right 
upper and lower extremities, but 4/5 in left upper and lower 
extremities. Sensation was intact bilaterally to light touch. 
Finger-to-nose was dysmetric on the left. Biceps and patellar 
reflexes were 1/4 on the left and 2/4 on the right. Babinski 
reflex was absent and Hoffman reflex was present on the left. 
Given focal neurological findings, magnetic resonance imag-
ing (MRI) of the brain, MRI of the cervical spine (Figures 1 
and 2), and lumbar puncture (LP) were performed. Magnetic 
resonance imaging RI of the brain with and without contrast 
showed no acute intracranial process.
Lumbar puncture showed pleocytosis with lymphocytic 
predominance and a normal glucose and protein. 
Cerebrospinal fluid was negative for oligoclonal bands, 
organisms, neoplastic cells, and inflammatory biomarkers. 
Serologic testing was negative for cytomegalovirus, human 
immunodeficiency virus, Lyme, syphilis, and herpes simplex 
virus. Based on MRI and LP findings, there was suspicion 
for MS or transverse myelitis causing symptoms, albeit an 
atypical presentation. Neoplasm or vasculitis was considered 
unlikely. Therefore, an anti-aquaporin-4 (AQP4) receptor 
antibody titer was ordered and was found to be elevated 
with titers >80 units/mL. This is a very disease-specific 
autoantibody for neuromyelitis optica (NMO) and thus led 
us to the diagnosis of NMOSD.
The patient was treated with methylprednisolone 1 g intra-
venous daily for 3 days followed by plasmapheresis for 6 
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sessions. She was discharged with neurology follow-up 
outpatient.
Discussion
Neuromyelitis optica, also known as Devic’s disease, is an auto-
immune demyelinating disorder of the central nervous system. 
The disorder was first described in 1870 and was confused with 
MS for many years. The distinction between NMO and MS is 
made based on pathogenesis, antibody studies, imaging, and 
response to treatment. The advent of NMO-IgG/AQP4 was 
pivotal in differentiating the 2 disease entities. This distinction 
is important not only for nomenclature but also for therapeutic 
decisions as some immunotherapeutic agents used for treat-
ment of MS can aggravate the symptoms of NMO.2
The International Panel for NMO Diagnosis (IPND) 
revised diagnostic criteria which defined the term NMOSD. 
The term NMOSD was introduced in 2007 to include 
patients presenting with atypical form of the disease and were 
positive for AQP4-IgG serology, those with AQP-IgG sero-
positivity and concomitant autoimmune disorders, and those 
with cerebral, diencephalic, and brainstem lesions occurring 
in patients with typical NMO. In 2015, IPND unified the 
term NMO and NMOSD and developed the new diagnostic 
criteria of NMOSD based on the occurrence of core clinical 
Figure 1. Postcontrast sagittal and axial views of the cervical spine. Read as a focal area of abnormal enhancement within the spinal cord extending from 
the cranio-cervical junction at level of C3-C4, extending for a length of approximately 5 cm.
Figure 2. Repeat postcontrast sagittal and axial views of the cervical spine, 4 months after previous magnetic resonance imaging. Read as abnormal 
signal intensity in the left side of the cord without enhancement.
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characteristics with or without detection of AQP4 antibody.3 
The core clinical characteristics include the following: (1) 
optic neuritis, (2) acute myelitis, (3) area postrema syndrome, 
(4) acute brainstem syndrome, (5) symptomatic narcolepsy or 
acute diencephalic clinical syndrome with NMOSD-typical 
diencephalic MRI lesions, and (6) symptomatic cerebral syn-
drome with NMOSD-typical brain lesions.3 Patients without 
AQP4-IgG seropositivity have more strict criteria which 
include 2 or more core clinical characteristics and specific 
MRI characteristics. A longitudinally extensive transverse 
myelitis (LETM) extending over 3 or more vertebral seg-
ments, as in our patient, is the most specific neuroimaging 
characteristic of NMOSD and very uncommon in patients 
with MS.4 The application of the 2015 criteria was studied by 
Hamid et al in patients with NMO and non-MS demyelinat-
ing disorders from 2006 to 2015. They noted an increase in 
the diagnosis of NMOSD by 76%. This increase was largely 
due to the introduction of AQP4 serology testing.5
In 2006, serology testing for AQP4 was incorporated into 
the diagnostic criteria for NMO to improve diagnostic accu-
racy.4 The AQP4 serum autoantibody, also known as NMO-
IgG, has a sensitivity of 91% and specificity of 100% for NMO 
and is positive in up to 80% of patients.3 The AQP4 is a water 
channel in the brain, which is highly localized in astrocytes. 
These antibodies may be responsible for a variety of immune 
events which includes immunoglobulin deposition, demyelina-
tion, and complement-mediated cytotoxicity.6 The develop-
ment of new antigenic targets such as AQP1 and myelin 
oligodendrocyte glycoprotein in AQP4-seronegative patients 
may allow for novel treatment options.7
Acute attacks are treated with intravenous glucocorticoids, 
followed by plasma exchange for refractory cases, such as our 
patient. Recurrent attacks are treated with long-term immuno-
suppression. There are multiple empiric immune-modulating 
therapeutic options employed. However, none have been 
proven effective in prospective trials or led to the development 
of complicated infections.8 Immunosuppression is continued 
for at least 5 years in seropositive patients presenting with an 
initial attack, as they are at high risk for relapse. At this time, 
there is no consensus as to the total duration of therapy.
The recommended agents include oral azathioprine or 
mycophenolate mofetil, with or without oral steroids.9 At pre-
sent, seronegative and seropositive NMOSDs are managed 
similarly. The complement fixation pathway, which includes 
antibody formation and activating the membrane attack com-
plex, plays a key role in NMOSD relapses. Thus, restoring the 
loss of immune tolerance is fundamental in developing novel 
NMOSD treatment modalities.10 New therapies such as anti-
IL6 receptor, anticomplement, and anti-AQP4 antibody bio-
logicals are promising future options.11
The long-term disability and mortality rates of NMOSD 
are high and there is a stepwise deterioration of function. A 
retrospective review by Kleiter et  al12 demonstrated that 
remission rates were higher in isolated optic neuritis as 
compared with isolated myelitis and for unilateral versus 
bilateral optic neuritis.12 Factors indicative of a poor progno-
sis include the number of relapses in the first 2 years, the 
severity of first attack, presence of other autoimmune condi-
tions, and older age at onset.11 Neurogenic respiratory failure 
is most frequently the cause of death. The use of AQP4 
autoantibody as a marker of disease progression is presently 
being studied but no data are available to suggest its appropri-
ateness in current practice. Weinshenker et  al performed a 
prospective study with patients who initially presented with 
LETM. Of 29 patients, 11 were found to be seropositive and 
at 1-year follow-up, 5 of the 9 seropositive patients developed 
a recurrence. Of the 14 patients who were seronegative at 
diagnosis, there were no reported recurrences or case reports 
of optic neuritis.13
Our patient presented with a rare manifestation of 
NMOSD, that is, older age of onset without ophthalmologic 
symptoms. Herein, we highlight the importance of recognizing 
unusual presentations of NMOSD and the need for early iden-
tification and treatment.
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